Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Texas Measure Cuts HIV Funds, Boost Abstinence Education

By Drug Discovery Trends Editor | April 1, 2015

Texas would cut $3 million from programs to prevent HIV and other sexually transmitted diseases and spend that money instead on abstinence education under a contentious Republican-sponsored measure tucked into the state budget Tuesday night.
 
The GOP-controlled House overwhelmingly approved the budget amendment, but not before a tense exchange with Democrats that veered into the unusually personal.
 
Republican state Rep. Stuart Spitzer, a doctor and the amendment’s sponsor, at one point defended the change by telling the Texas House that he practiced abstinence until marriage. The first-term lawmaker said he hopes schoolchildren follow his example, saying, “What’s good for me is good for a lot of people.”
 
Democrat state Rep. Harold Dutton asked Spitzer if abstinence worked for him.
 
Shouts of “Decorum!” soon echoed on the House floor as Spitzer responded and the back-and-forth intensified. Efforts by Democrats to put the debate in writing for the record – usually a perfunctory request – failed.
 
The measure is a long way from final approval. It must still survive budget negotiations with the Senate, although that chamber is equally dominated by conservatives.
 
Texas in 2013 had the third-highest number of HIV diagnoses in the country, according to the federal Centers for Disease Control. Texas also has one of the highest teen birth rates, and its public schools are not required to teach sex education.
 
Another Republican-sponsored amendment that passed Tuesday night would prevent schools from distributing sex education materials from abortion providers.

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50